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Abstract
A suppressor of galactose toxicity in a gal7 yeast strain (lacking galactose 1-phosphate uridyl transferase) has been isolated
from a HeLa cell cDNA library. Analysis of the plasmid clone indicated that the insert has an ORF identical to that of
hIMPase (human myo-inositol monophosphatase). The ability of hIMPase to suppress galactose toxicity is sensitive to the
presence of Li in the medium. A gal7 yeast strain harboring a plasmid containing cloned hIMPase grows on galactose as a
sole carbon source. hIMPase mediated galactose metabolism is dependent on the functionality of GAL1 as well as GAL10
encoded galactokinase and epimerase respectively. These results predicted that the UDP-glucose/galactose pyrophos-
phorylase mediated pathway may be responsible for the relief of galactose toxicity. Experiments conducted to test this
prediction revealed that expression of UGP1 encoded UDP-glucose pyrophosphorylase can indeed overcome the relief of
galactose toxicity. Moreover, expression of UGP1 allows a gal7 strain to grow on galactose as a sole carbon source. Unlike
the hIMPase mediated relief of galactose toxicity, UGP1 mediated relief of galactose toxicity is lithium insensitive. Based on
our results and on the basis of available information on galactose toxicity, we suggest an alternative explanation for the
molecular mechanism of galactose toxicity. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Conversion of galactose to glucose is a evolutio-
narily conserved process. This metabolic process is
mediated by the Leloir enzymes and de¢ciency in
any of these enzymes gives rise to an inherited auto-
somal recessive disorder called galactosemia [1]. It
occurs at a frequency of 1:30 000 to 1:60 000 in the
general population [1,2]. Galactosemia has been cate-
gorized into three types, of which classical galactose-
mia is the most common form which is due to the
de¢ciency of galactose 1-phosphate uridyl transferase
encoded by GALT [1,2].
Classical galactosemia, a potentially lethal disor-
der, is well studied and yet not well understood in
terms of the metabolic and biochemical basis of its
diverse phenotypes [3]. Available data strongly sug-
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gest that accumulation of galactose 1-phosphate
(Gal-1-P) is the primary cause of classical galactose-
mia [4]. While the most common treatment of dietary
restriction of galactose relieves acute symptoms, long
term defects such as developmental de¢ciencies,
ovarian failure, mental disabilities, speech defects,
etc. still persist [1^3]. Although the biochemical
basis of Gal-1-P mediated toxicity is not clearly
understood, it is becoming increasingly clear that
the long term defects observed in treated patients
are due to the endogenous production of Gal-1-P
[4].
Studies in model systems only serve to emphasize
the need to develop an animal model, such as a
transferase de¢cient mouse, to decipher the underly-
ing biochemical mechanisms of classical galactosemia
[4]. Since the GALT de¢cient mouse does not mani-
fest any of the symptoms shown by the patients suf-
fering from galactosemia [5], a better de¢ned genetic
model is needed to understand the biochemical and
metabolic basis of galactosemia.
The yeast Saccharomyces cerevisiae has played a
signi¢cant role in the cloning, expression and the
study of structure-function relationship of Leloir en-
zymes from humans [6^10]. Analogous to humans, a
yeast strain defective in GAL7 (corresponding to
GALT in humans) exhibits galactose toxicity in the
presence of galactose and is unable to grow on alter-
native carbon sources such as glycerol due to the
accumulation of Gal-1-P [11]. This feature, and given
that yeast is a genetically and biochemically more
amenable system, prompted us to examine some fac-
ets of galactosemia.
Genetic suppression of galactose toxicity due to
the reduction in the expression of GAL1 promoter
mediated function has been used to isolate genes
that encode regulatory proteins [12,13]. We reasoned
that it may be possible to isolate genes from humans
that can suppress the above phenotype, by reducing
the formation or accumulation of Gal-1-P below the
threshold required to manifest galactose toxicity.
Characterization of the suppressors that sequester,
hydrolyze or metabolize to reduce Gal-1-P accumu-
lation was expected to provide valuable information
towards understanding the biochemical basis of clas-
sical galactosemia. This attempt resulted in the iso-
lation of human myo-inositol monophosphatase
(hIMPase) as the suppressor of galactose toxicity in
yeast. Biochemical and genetic studies were carried
out to de¢ne the mechanism of this suppression.
These studies suggest that hIMPase might be an im-
portant target for the Gal-1-P mediated toxicity syn-
drome in classical galactosemia.
2. Materials and methods
2.1. Strains and plasmids
Escherichia coli strains DH5K and XL1-Blue
MRFP were used for routine recombinant DNA
work. Yeast strains YM147 (K ade 2-101 ura 3-52
trp 1-289 gal1) [14], Sc289 (K ade2-101 ura3-52 trp
1-289 gal7v102) and Sc652 (a ade 2-101 ile ura3-52
leu 2-3,112 trp 1-HIII, his3v-1 MEL1) [15] were gifts
from James E. Hopper. Yeast strain PJB5 (a ade 2-
101 ile ura3-52 leu 2-3,112 trp 1-HIII, his3v-1 MEL1-
gal10: :LEU2) is derived from Sc652 by disrupting
the GAL10 locus as described [14]. Plasmids pUC19
and YEplac181 [16] were used for general cloning
purposes. pWJ220 carries a cassette to disrupt the
genomic locus of GAL10 [14]. Plasmid pYEJBGAL1
carries the yeast GAL1 gene under the CYC1 pro-
moter in YEp24 [17]. The GAL7 gene in YEp24
(GAL7) isolated from yeast genomic library was a
gift from James E. Hopper. Yeast expression vectors
p416TEF (p416) and p426TEF (p426) were gifts
from Martin Funk [18]. These expression vectors
are pBLUESCRIPT based plasmids carrying TEF
promoter for expression of homologous/heterologous
proteins in yeast. Plasmids p416 and p426 carry
URA3 as the selectable marker for yeast. All of
them carry an ampicillin resistance marker for prop-
agation in E. coli. Plasmid p416 is a low-copy ex-
pression vector whereas p426 is multi-copy expres-
sion vector. pNV11, a human cDNA expression
library, was a gift from Kuniharo Matsumoto
[19]. It is a 2 Wm based multi-copy shuttle vector
consisting of URA3 as the selectable marker for yeast
and ampicillin resistance marker for E. coli. The
cDNAs were expressed from yeast TDH promoter.
Plasmid pJMGal2W (gift from J. Franc,ois) carries
UGP1 under the control of the GAL10/CYC1 pro-
moter. It has URA3 and ampicillin resistance as the
selectable marker for yeast and E. coli, respectively
[20].
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2.2. Chemicals
X-gal (5-gromo-4-chloro-3-indolyl-L-D-galactopyr-
anoside) and IPTG (isopropyl-K-D-thiogalactopyra-
noside) were purchased from Genei (Bangalore, In-
dia). T4 DNA ligase, DNA polymerase (Klenow
fragment), CIAP (calf intestinal alkaline phospha-
tase), restriction enzymes and dNTPs were purchased
from Amersham (Arlington Heights, IL, USA).
Yeast extract, Bacto-peptone, nitrogen base without
amino acids were bought from Difco (Detroit,
MI, USA). Agar, Tris-HCl, EDTA, BSA, galactose,
galactose 1-phosphate, glucose, amino acids, ATP,
p-nitrophenyl phosphate (pNPP), MgCl2 were pur-
chased from Sigma (St. Louis, MO, USA) and
other chemicals used in this study were of the highest
grade commercially available. 14C-Labelled galactose
1-phosphate was purchased from DuPont NEN
(catalog number NEC579) and had a speci¢c activ-
ity of 352.7 mCi/mmol and a concentration of 0.02
mCi/ml.
2.3. Media and growth conditions
Yeast strains were propagated and maintained as
described [21]. Yeast strains were propagated either
in YEPD (0.5% yeast extract, 1% Bacto-peptone and
2% glucose) or synthetic media. Synthetic media were
prepared by mixing either complete amino acids mix-
ture (Comp) or amino acids mixture lacking either
uracil (Ura3) or leucine (Leu3) with yeast nitroge-
nous base without amino acids. Final concentrations
of amino acid mixture and yeast nitrogen base were
700 mg/l and 6.7 g/l, respectively. Carbon sources
were added to the synthetic media to ¢nal concen-
trations of 2% (w/v) glucose (Glu), 3% (v/v) glycerol
(Gly), 1.5% (w/v) galactose (Gal) or Gly+0.05% (w/v)
galactose (Gly/Gal). E. coli strains were grown in LB
(1% tryptone, 0.5% yeast extract and 1% NaCl, pH
7.0) medium for general propagation and ampicillin
at a ¢nal concentration of 100 Wg/ml was supple-
mented when required for plasmid maintenance.
Yeast strains were transformed by the lithium acetate
method while E. coli competent cells were made us-
ing CaCl2 [22].
2.4. Isolation of pDKJ132 as a suppressor of
galactose toxicity
Galactose is toxic to Sc289 and hence it cannot
utilize alternative carbon sources such as glycerol in
the presence of galactose. This is because of Gal-1-P
accumulation in the absence of GAL7 encoded gal-
actose 1-phosphate uridyl transferase [11]. It was
transformed with pNV11 (cDNA library) and trans-
formants capable of growing in Ura3 Glu medium
were selected. These transformants were then repli-
cated onto Ura3 plates containing 0.05% galactose
and 3.0% glycerol (Ura3 Gly/Gal). Transformants
capable of growing were picked up from approxi-
mately 300 000 transformants and subjected to a
plasmid-loss experiment. This method di¡erentiates
between spontaneous genomic mutations and plas-
mid linked suppression of galactose toxicity. Only
one transformant showed plasmid linked suppression
of galactose toxicity. The plasmid from the above
transformant was isolated and was named
pDKJ132. Retransformation of Sc289 with
pDKJ132 con¢rmed that suppression of galactose
toxicity is a plasmid-borne trait.
2.5. Recombinant DNA work
All recombinant DNA manipulations were done as
described [22]. pDKJ132-181 was constructed by
cloning the 2.2 kb XhoI fragment, containing the
full length cDNA insert of pDKJ132, at the SalI
site of YEplac181. pDKJ132vXhoI is a derivative
of pDKJ132 lacking the 2.2 kb cDNA insert. It
was constructed by digesting pDKJ132 with XhoI
and religating the vector backbone. The cDNA insert
was cloned at the unique SalI site of p416TEF and
p426TEF to give p416-132 and p426-132, respec-
tively.
2.6. DNA sequencing
Plasmid pDKJ132-181 was sequenced at the auto-
mated DNA sequencing facility at the Indian Insti-
tute of Science, Bangalore, India. M-13 forward and
reverse primers as well as internal primers PJB1p (5P-
CCA GAG ACT GTG AGA ATG G-3P), PJB4p (5P-
CCA TTC TCA CAG TCT CTG G-3P), PJB9p (5P-
GGA TGT ATG ATA TGC CTG G-3P), PJB10p
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(5P-CCA GGC ATA TCA TAC ATC C-3P), PJB11p
(5P-CAG AAT CCA GCG GCA ATG-3P), PJB12p
(5P-CAT TGC CGC TGG ATT CTG-3P) were used
to sequence pDKJ132-181.
2.7. Enzyme assays
IMPase assays were performed with cell extracts
made from yeast transformants harboring appropri-
ate plasmids, using pNPP as the substrate [23]. Mid
log phase cells of Sc289 transformed with yeast ex-
pression plasmids were used to prepare cell extracts
using the glass bead method. Since hIMPase has
been shown to be heat stable [24], heat shock was
given for 15 min at 75‡C and the protein precipitate
was removed by centrifugation at 10 000 rpm at 4‡C
for 20 min. The supernatant was used for the enzyme
assays. The above protocol had to be used to reduce
the non-speci¢c hydrolytic activity present in the cell
extract. Di¡erent volumes of cell extracts were added
to a 0.5 ml reaction mixture containing 50 mM Tris-
HCl (pH 7.5), 1 mM MgCl2 and 0.1 mM EGTA.
pNPP was used as the substrate at a ¢nal concentra-
tion of 5 mM. The reaction was terminated by add-
ing 0.9 ml of a 0.1 M KOH solution to 0.1 ml of
reaction mixture. LiCl at 100 mM was used in the
reaction to measure the lithium sensitive activity. The
reaction was found to progress at a linear rate for at
least 5 h. The reaction was carried out for 3 h at
37‡C. Absorbance at 405 nm was recorded as a
measure of enzymatic activity, to determine the
amount of p-nitrophenol released.
The assay for UDP-galactose pyrophosphorylase
was done according to the protocol developed by
Abraham and Howell [25]. Sc289 cells harboring ap-
propriate plasmids were grown in medium containing
Ura3 Gly until mid log phase. Galactose was added
to cells harboring cloned IMPase or UGP1 to a ¢nal
concentration of 0.1% and were subsequently al-
lowed to grow for a further 2 h. Cells were harvested
and cell extracts were prepared using glass beads.
The extracts obtained were used for enzyme assays.
The reaction mixture contained 50 mM Tris-HCl
(pH 8.3), 10 mM MgCl2, 5 mM DTT, 4 mM UTP
and 19 WM Gal-1-P. The Gal-1-P solution was made
by mixing 100 Wl of 14C-labelled Gal-1-P (speci¢c
activity 352.7 mCi/mmol and concentration 0.02
mCi/ml) to 900 Wl of 15 WM ‘cold’ Gal-1-P. As IMP-
ase has been shown to hydrolyze Gal-1-P, LiCl at a
concentration of 10 mM was added, to inhibit this
reaction. The reaction was initiated by the addition
of 10 Wl of cell extract to 10 Wl of pre-mix solution.
The activity was found to be linear for at least 1 h.
All reactions were carried out at 30‡C, for 30 min
and in quadruplicate. The reaction was stopped by
heat inactivation. One unit of alkaline phosphatase
suspended in 2 Wl bu¡er was added to each tube and
incubated at 37‡C for 30 min to hydrolyze unused
Gal-1-P remaining in the solution. An independent
experiment had shown that 1 U of alkaline phospha-
tase was su⁄cient to hydrolyze the remaining Gal-1-
P. The phosphatase reaction was stopped by heat
inactivation. An 11 Wl sample from the reaction vol-
ume was applied to a DEAE-cellulose disc (DE-81,
2.4 cm in diameter, Whatman). The disc was dried at
37‡C for about 2 h and then washed with double
distilled water thrice to remove unbound sugar.
The disc was dried again before measuring the radio-
activity in the DE-81 paper containing UDP-galac-
tose formed during the reaction. The radioactivity
incorporated was counted using a LKB liquid scin-
tillation counter. Upon repeating the experiments in
quadruplicate for three times a deviation of 10% was
observed. Protein was estimated by the Bradford as-
say [26] with appropriately diluted protein samples.
The OD was measured at 595 nm with BSA as stand-
ard.
3. Results
3.1. hIMPase is the suppressor of galactose toxicity
Preliminary restriction enzyme analysis of the plas-
mid clone pDKJ132 revealed that the cDNA insert
can be liberated as a 2.2 kb XhoI fragment. Plasmid
pDKJ132-181 was used as a template to sequence
both the strands of the ORF present in the cDNA
insert. The DNA sequence was used to search for
homologous sequences in GenBank using the
BLAST. The sequence was found to be identical to
the reported hIMPase sequence [24]. Since the size of
the cDNA present in pDKJ132 was found to agree
with the size of hIMPase mRNA [24], we inferred
that the cloned gene represents the full length
cDNA of hIMPase. To examine the dosage e¡ect,
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the full length cDNA was sub-cloned into low-copy
as well as multi-copy yeast expression vectors. It was
found that expression from a multi-copy expression
vector is necessary to relieve galactose toxicity (Fig.
1, compare p416-132 with p426-132).
Lithium salts are known to inhibit IMPase activity
in vitro [27]. In order to test whether the ability of
hIMPase to suppress galactose toxicity was sensitive
to Li salts, various concentrations of LiCl were
added to the media (Fig. 1). It was observed that
Li, even at a concentration of 2 mM, restores gal-
actose toxicity. Suppression of galactose toxicity by
hIMPase was found to be sensitive to LiCl at con-
centrations close to its IC50 (1.6 mM) [28]. These
results suggest that IMPase activity per se is required
for the relief of galactose toxicity.
To con¢rm that hIMPase is expressed in yeast,
enzyme assays were performed on extracts obtained
from Sc289 cells bearing either the plasmid pDKJ132
or pDKJ132vXhoI (vector control). The hydrolytic
activity in extracts obtained from cells bearing
hIMPase was found to increase as a function of pro-
tein concentration (Fig. 2). The activity was also
found to be inhibited by Li con¢rming that the hy-
drolytic activity is due to the expression of hIMPase.
It is clear from our studies that overexpression of
hIMPase relieves galactose toxicity in a gal7 yeast
strain through one or more of the following mecha-
nisms: (a) IMPase facilitates metabolism of galac-
tose, thereby reducing Gal-1-P accumulation, (b)
IMPase reduces the accumulation of Gal-1-P. This
could be due to interference with galactose uptake,
expression of galactokinase, etc. (c) A combination
of the above two possibilities.
3.2. hIMPase bypasses a gal7 block in galactose
metabolism
If relief of galactose toxicity in Sc289 bearing
Fig. 1. Relief of galactose toxicity in Sc289 harboring hIMPase
and e¡ect of lithium. 105 cells of Sc289 transformants bearing
plasmids GAL7 (GAL7 gene in YEp24), p426 (control), p416-
132 (low-copy) and p426-132 (multi-copy) were spotted on to
Ura3 Gly or Ura3 Gly/Gal plates with di¡erent concentrations
of LiCl as shown.
Fig. 2. Determination of hIMPase activity. pNPP hydrolytic ac-
tivity of cell extracts from cells bearing pDKJ132, in the ab-
sence (U) and presence of 100 mM LiCl (O). E and W repre-
sent hydrolytic activity from cells bearing pDKJ132vXhoI with
and without LiCl respectively.
Fig. 3. Utilization of galactose as the sole carbon source by
Sc289 transformants harboring hIMPase. Sc289 transformants
bearing indicated plasmids grown in Ura3 Glu were replicated
onto di¡erent plates as indicated.
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hIMPase is due to galactose metabolism, it is ex-
pected that Sc289 bearing hIMPase would grow in
galactose as a sole carbon source. Sc289 bearing
hIMPase (p426-132) was indeed able to grow on
galactose as the sole carbon source (Fig. 3), and its
growth on galactose was sensitive to lithium (Fig. 3),
indicating involvement of hIMPase in this process.
This result clearly suggests that IMPase does not
interfere in the uptake of galactose. The fact that
Sc289 bearing hIMPase can utilize galactose as the
sole carbon source indicates that either galactose or
Gal-1-P is being metabolized. In either case galactose
toxicity is expected to be abolished.
3.3. hIMPase cannot bypass a gal1 or gal10 block in
galactose metabolism
To determine whether galactose or Gal-1-P is
being metabolized, YM147, a gal1 yeast strain (lack-
ing galactokinase), was transformed with either vec-
tor alone or with a plasmid bearing hIMPase. If the
transformant bearing hIMPase grows in galactose,
then it can be inferred that galactose and not galac-
tose 1-phosphate is metabolized. On the other hand,
if it does not grow in galactose, it can be inferred
that Gal-1-P is metabolized. It was found that
YM147 bearing hIMPase expression plasmid, p426-
132, could not grow on galactose as the sole carbon
source (Fig. 4). This result suggested that YM147
bearing hIMPase metabolizes Gal-1-P rather than
galactose.
If hIMPase metabolizes Gal-1-P independent of
GAL10 encoded epimerase, it is expected that a
gal10 yeast strain harboring hIMPase would grow
on galactose, similar to a gal7 yeast strain. However,
PJB5, a gal10 yeast strain, harboring hIMPase was
unable to grow in the presence of galactose (Fig. 5).
This result demonstrates that GAL10 encoded epi-
merase function is necessary for IMPase mediated
metabolism of Gal-1-P in a gal7 yeast strain. The
relief of toxicity in Sc289 by hIMPase could be be-
cause of the reduction of Gal-1-P due to its metab-
olism. Alternatively, in Sc289 bearing hIMPase, gal-
actose metabolism occurs due to the relief of
galactose toxicity and galactose metabolism per se
may not be responsible for the relief of galactose
toxicity.
3.4. Expression of hIMPase modulates
UDP-galactose pyrophosphorylase activity
Regardless of the cause and e¡ect relationship be-
tween Gal-1-P toxicity and Gal-1-P metabolism, it
was necessary to determine the pathway of Gal-1-P
metabolism in Sc289 harboring multiple copies of
hIMPase. The only possible route for the metabolism
of Gal-1-P other than GAL7 but involving epimerase
reaction is mediated by UDP-galactose pyrophos-
phorylase. The reaction catalyzed by UDP-galactose
Fig. 4. E¡ect of expression of hIMPase and UGP1 in YM147
(gal1). Strain YM147 transformants bearing GAL1 (pYEJB-
GAL1), p426 (control), p416-132 (low-copy) and p426-132
(multi-copy) and UGP1 (pJMGal2W) were replicated onto dif-
ferent plates as indicated.
Fig. 5. E¡ect of hIMPase and UGP1 expression in PJB5
(gal10). Strain PJB5 transformants bearing plasmids p426 (con-
trol), p416-132 (low-copy), p426-132 (multi-copy) and UGP1
(pJMGal2W) were replicated onto di¡erent plates as indicated.
Wild-type strain Sc652 (parent strain of PJB5), transformed
with p426 (control plasmid), was taken as the positive control.
BBADIS 61843 29-7-99
D.V. Mehta et al. / Biochimica et Biophysica Acta 1454 (1999) 217^226222
pyrophosphorylase (EC 2.7.7.10) is :
Gal-1-PUTPHUDP-Gal PPi
Although the activity of this enzyme in yeast was
reported in 1953 [29], to date the gene encoding this
enzyme has not been identi¢ed. It is assumed that the
UDP-glucose pyrophosphorylase has a broader sub-
strate speci¢city and can also catalyze the reaction of
UDP-galactose pyrophosphorylase [30,31]. Thus, in a
gal7 background, Gal-1-P can be metabolized by a
combination of two enzyme activities, epimerase en-
coded by GAL10 and UDP-glucose/galactose pyro-









If such a scheme is operational in a gal7 yeast
strain harboring IMPase, then neither a gal10 nor a
gal1 yeast strain harboring IMPase is predicted to
grow on galactose. Our results are consistent with
these predictions (see Section 3.3). A gal7 yeast strain
harboring IMPase in the presence of galactose would
have su⁄cient galactokinase (GAL1 gene product) to
convert galactose to Gal-1-P as well as epimerase
(GAL10 gene product) to convert UDP-Gal to
UDP-Glu. However, a gal7 strain, otherwise wild-
type, is not able to grow on galactose unless IMPase
is overexpressed. It is possible that the endogenous
UDP-glucose/galactose pyrophosphorylase may not
be su⁄cient or active to metabolize Gal-1-P in a
gal7 yeast strain.
Therefore, we wanted to determine the role of
UGP1, encoding UDP-glucose pyrophosphorylase,
in the alternative pathway of galactose metabolism.
For this purpose, yeast strains Sc289 (gal7), YM147
(gal1) and PJB5 (gal10) were transformed with plas-
mid pJMGal2W expressing UGP1 under a GAL10/
CYC1 promoter and the e¡ect on galactose toxicity
was determined. It was found that overexpression of
UGP1, like hIMPase, relieves galactose toxicity in
Sc289 (Fig. 6). Consistent with our hypothesis,
UGP1 expression in a gal1 or gal10 background
did not confer growth on galactose (Figs. 4 and 5).
If UGP1 relieves galactose toxicity by metabolizing
galactose 1-phosphate, then it is expected that a gal7
mutant strain bearing only UGP1 should grow on
galactose as a sole carbon source. However, it has
been shown that overexpression of UGP1 under the
GAL10 promoter causes retarded growth in the pres-
ence of 2% galactose as the sole carbon source [20].
Therefore, we determined whether a gal7 strain bear-
ing pJMGal2W could grow on 6 2% galactose. gal7
strain bearing UGP1 was found to grow well on
0.25% galactose as a sole carbon source (Fig. 6).
The above pathway has been proposed to be respon-
sible for the metabolism of galactose in a galactose-
mic patient [32] and our results represent a parallel
extension in yeast.
We also considered the possibility that overexpres-
Table 1
Determination of UDP-galactose pyrophosphorylase activity in
vitro
Plasmid Carbon source Activitya
p426 (control) Glycerol 25 (100%)
p426 (control) Glycerol+galactose 34 (139%)
p426-132 (hIMPase) Glycerol 33 (135%)
p426-132 (hIMPase) Glycerol+galactose 44 (180%)
pJMGal2W (UGP1) Glycerol 37 (100%)
pJMGal2W (UGP1) Glycerol+galactose 183 (489%)
Enzyme assays were carried out using cell extracts obtained
from Sc289 transformants bearing indicated plasmids as men-
tioned in Section 2. Numbers in parentheses indicate relative
activity.
aActivity is expressed as pmol of UDP-galactose formed per mg
protein per 30 min.
Fig. 6. E¡ect of UGP1 and hIMPase expression in Sc289.
Sc289 transformants bearing GAL7 (GAL7 in YEp24), p426
(control), p416-132 (low-copy), p426-132 (multi-copy) and
UGP1 (pJMGal2W) were replicated onto di¡erent plates as indi-
cated.
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sion of IMPase relieves galactose toxicity by modu-
lating UDP-glucose/galactose pyrophosphorylase ac-
tivity. To test this, we examined the level of UDP-
galactose pyrophosphorylase activity from yeast cells
harboring IMPase. UDP-galactose pyrophosphoryl-
ase activity was found to be elevated in cells harbor-
ing hIMPase (Table 1) as compared to the vector
control. However, enzyme activity was also higher
in cells grown in galactose as compared to glycerol
alone. The activity was substantially higher in cells
bearing hIMPase compared to its absence and also
grown in presence of galactose. These results indicate
that both hIMPase and galactose positively modulate
activity of UDP-galactose pyrophosphorylase inde-
pendently. As a positive control, UDP-galactose
pyrophosphorylase activity was determined in cells
harboring UGP1 in the presence of glycerol and
galactose (Table 1). Our results are consistent with
the earlier observation that UDP-glucose pyrophos-
phorylase also has UDP-galactose pyrophosphoryl-
ase activity [30,31].
4. Discussion
To date, the biochemical basis underlying galac-
tose toxicity in classical galactosemia remains an
enigma. This is largely due to the lack of proper
experimental models to understand the biochemical
and metabolic basis of galactose toxicity. Based on
cyclical phosphorylation and dephosphorylation of
galactose in uridyl transferase de¢cient human ¢bro-
blasts [33], red blood cells [34,35] and chicken brain
[36], it has been suggested that the toxicity is due to
depletion of energy. Another proposal is that the
toxicity is due to the inhibition of the enzymes of
carbohydrate metabolism by Gal-1-P. This view is
based mainly on observations in vitro (reviewed in
[4]). Impairment in the galactosylation of glycolipids
and glycoproteins of various tissues suggested that it
could be another causative factor for the long term
neurological defects observed in galactosemic pa-
tients. Results of GALT expression in rats during
the embryonic and postnatal periods are consistent
with the above proposal ([37], see review [3]).
To understand the molecular basis of galactose-
mia, mice de¢cient in GALT have been generated
[5]. These mice do not have symptoms that are rem-
iniscent of galactosemia despite the accumulation of
comparable amounts of Gal-1-P in the tissues. Based
on this, it has been suggested that GALT de¢cient
mice could serve as a better model, if the reasons for
the lack of symptoms can be determined. It seems
unlikely that the toxicity in galactosemic patients is
only due to Gal-1-P accumulation. If this were the
case, GAL7 de¢cient mice that accumulate compara-
ble amounts of Gal-1-P as humans should also have
been a¡ected.
Based on our observations, we suggest that IM-
Pase is one of the key elements of Gal-1-P mediated
toxicity in galactosemic patients. Our observation is
further supported by the following facts. (a) It has
been observed that inositol is depleted in galactose-
mic patients (reviewed in [38]). (b) Recently, based
on the observation that Gal-1-P is as good a sub-
strate as inositol monophosphate for IMPase from
human, rat and bovine brains, it has been suggested
that the function of IMPase must include a possible
role for IMPase in the regulation of galactose metab-
olism in vivo [39]. (c) Our observation that overex-
pression of hIMPase alleviates galactose toxicity in a
lithium sensitive manner suggests that IMPase func-
tion is important for the modulation of intracellular
levels of Gal-1-P.
In light of our observations and available data, we
suggest a novel biochemical mechanism for the toxic
e¡ects of Gal-1-P in galactosemic patients. In galac-
tosemic patients, accumulated Gal-1-P could act as a
substrate for IMPase, thereby interfering with its
normal function. The phosphoinositide mediated
cell signalling plays a crucial role in the regulation
of a variety of biological processes. The hydrolysis of
phosphatidylinositol 4,5-bisphosphate (PIP2) by
phospholipase C generates D-1,4,5-inositoltriphos-
phate (1,4,5-IP3) and diacylglycerol which act as sec-
ond messengers in the target cell. 1,4,5-IP3 ¢nally
gives rise to inositol 4-phosphate, inositol 1-phos-
phate and inositol 3-phosphate [40]. IMPase plays a
crucial role in the hydrolysis of these inositol mono-
phosphates to free inositol which is then reused for
the synthesis of PIP2. This recycling is particularly
important in the brain, since (a) free inositol does not
enter the brain due to the blood-brain barrier and (b)
the brain has a limited capacity for de novo synthesis
of inositol (reviewed in [41]). Excess Gal-1-P accu-
mulation in galactosemic patients could interfere
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with the normal function of IMPase thereby causing
a disturbance in the phosphoinositide mediated sig-
nal transduction process. In consonance with this
function of IMPase, galactosemic patients are found
to su¡er from neurological abnormalities such as
mental retardation, learning disabilities, etc.
The alleviation of toxicity in Sc289 by UGP1 over-
expression may be due to the utilization of Gal-1-P
in the presence of UDP-glucose pyrophosphorylase
so that Gal-1-P may not accumulate above the
threshold required to interfere with the endogenous
IMPase function. As a corollary, in a gal7 strain
otherwise normal with respect to IMPase, endoge-
nous UDP-glucose pyrophosphorylase may not be
su⁄cient to reduce the Gal-1-P concentration below
the threshold. However, when hIMPase is overex-
pressed in Sc289, Gal-1-P toxicity is relieved, and
endogenous UDP-glucose pyrophosphorylase is suf-
¢cient to provide growth on galactose as the sole
carbon source. Therefore, we suggest that it is the
relative concentrations of Gal-1-P, IMPase and
UDP-glucose pyrophosphorylase that determine the
status of toxicity. It has been proposed that UDP-
galactose pyrophosphorylase, which constitutes only
5% of galactose 1-phosphate uridyl transferase in
adult liver, is engaged in the production of Gal-1-P
while in galactosemic patients it might be responsible
for the metabolism of Gal-1-P [42]. However, the
amount of UDP-galactose pyrophosphorylase in fe-
tal blood was almost 50% of uridyl transferase [42].
The fact that galactosemic patients do have the abil-
ity to metabolize galactose, albeit at a slower rate
[43], is consistent with the proposal that UDP-galac-
tose pyrophosphorylase may be involved in the uti-
lization of Gal-1-P. The observation that GALT
knockout mice are normal despite the accumulation
of Gal-1-P suggests that mechanisms other than gal-
actose metabolism could exist for the relief of galac-
tose toxicity in mice. It is conceivable that in mice
accumulation of Gal-1-P may not interfere with the
normal function of IMPase in signal transduction
pathway. Therefore, to understand the biochemical
mechanism of galactose toxicity better, it is impor-
tant to dissociate galactose utilization from relief of
Gal-1-P toxicity.
How does Gal-1-P interfere with the normal func-
tioning of IMPase to cause toxicity in yeast? Like
mammalian cells, yeast cells posses phosphoinositide
signalling mechanism and this pathway has been
shown to be essential for cell proliferation [44]. In-
hibition of IMPase using Li has been shown to
a¡ect biological processes such as development and/
or di¡erentiation in amphibia, zebra ¢sh, sea urchin
and slime mold [45]. In E. coli, it has been shown
that a mutation in the suhB gene product which en-
codes inositol monophosphatase a¡ects protein ex-
port, stress response, and DNA replication [46]. If
IMPase also has similar functions in yeast, interfer-
ence with this is expected to cause toxicity. There-
fore, IMPase function in yeast for Gal-1-P mediated
toxicity warrants further investigation.
Our data provide new insights into the reasons
why Gal-1-P exerts toxic e¡ects in galactosemic pa-
tients. On the basis of our experiments we suggest
that in addition to the primary defects that may re-
sult in Gal-1-P accumulation, impairment in other
enzymes such as IMPase UDP-galactose pyrophos-
phorylase and other Gal-1-P hydrolyzing enzymes
singly or in combination could exacerbate the spec-
trum of toxic e¡ects. Further investigations in this
direction are under way.
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